Author:
Dema Alissa*1, Reem Almaghrabi1, Imran Nizami1, Ghazwa Korayem2, Amal Saleh2, Amjad Alshamrani2, Norah Alrajeh2, Nour Albegami2, Reema Al Muraybidh2, Saba Bin Huwaimel2
Author address:
1 King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, 2 Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
Full conference title:
European Congress of Clinical Microbiology & Infectious Diseases 2019
Date: 17 August 2019
Abstract:
Background: Fungal infections remain one of the major causes of morbidity and mortality after lung transplantation. Inhaled amphotericin B is one of the prophylaxis modalities for fungal infection either alone or in combination with systemic antifungals that is employed by different transplant centers. There is no consensus regarding the dose, duration and frequency of nebulized amphotericin B. Breakthrough fungal infections has been reported mostly with fungi that are known to be resistant to amphotericin B. In this study, we aimed to evaluate safety and efficacy of using aerosolized amphotericin B in preventing fungal infection post lung transplantation.
Materials/methods: This was a retrospective, observational cohort study. We included all 132 lung transplant patients between 2010 and 2017 at King Faisal Specialist Hospital & Research Center (KFSH&RC). Eighty-Four patients received nebulized amphotericin B and met the inclusion criteria. The primary endpoint was occurrence of proven lung fungal infections within the first 12 months post transplantation which was defined as the presence of positive cultures or cytological fungal elements from respiratory specimen. Secondary endpoint was inhaled amphotericin B side effects. Data was collected from patients’ electronic medical records, using REDCap software. Statistical analysis was performed using SPSS software.
Results: All patients received prophylaxis for 3 months after lung transplantation. Breakthrough Aspergillosis infection occurred in 11 patients (13%). After the discontinuation of inhaled amphotericin B, six patients developed fungal infections within the first year after lung transplantation. The most common side effects reported were coughing (75%) and chest tightness (42%). Only one patient had neurological side effect manifested by Jerky movement which led to discontinuation of fungal prophylaxis.
Conclusions: Inhaled amphotericin B can be considered as an option for fungal prophylaxis post lung transplantation with relatively tolerable side effects.
Abstract Number: P2280
Conference Year: 2019
Link to conference website:
Link Conference abstract:
Link to talk:
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Mrs Ange Brennan (UK)
2024
n/a
-
v
Tianyu Lianga, Nir Osherovb, Ruoyu Lia, Qiqi Wanga, Wei Chena, Zhe Wana, Wei Liua*
2024
n/a
-
v
Jillian Simard, MD,1 Christopher Melani, MD,2
Rahul Lakhotia, MD,1
Michail S. Lionakis, MD
ScD,*,3
Stefania Pittaluga, MD PhD,4
James D. Phelan, PhD,*,1 Jagan R. Muppidi, MD
PhD,*,1
Lydia L. Chou, CRNP,*,1
Matthias Holdhoff, MD PhD,*,5 Michael Glantz, MD PhD,*,6
John A. Butman, MD PhD,*,7 Andrea Nicole Lucas, RN,*,8
Seth M. Steinberg, PhD,*,9
Elaine
S. Jaffe, MD,4
Louis M. Staudt, MD PhD,1
Wyndham H. Wilson, MD PhD,1 Mark Roschewski, MD102020
n/a
-
v
Mark Roschewski, MD,1
Christopher Melani, MD,2
Rahul Lakhotia, MD,3
Stefania Pittaluga, MD
PhD,4
James D. Phelan, PhD,*,3
Cody Peer, PhD,*,5 Michail S. Lionakis, MD ScD,*,6 Lydia
L. Chou, CRNP,*,3 Matthias Holdhoff, MD PhD,*,7 Michael Glantz, MD PhD,*,8 Jan Drappatz, MD,*,9
Catherine Lai, MD MPH,10 John A. Butman, MD PhD,*,11 Andrea Nicole Lucas, RN,*,12 Seth
M. Steinberg, PhD,*,13 William D. Figg, PhD,*,14 Elaine S. Jaffe, MD,4
S. Percy Ivy, MD,*,15
Richard F. Little, MDMPH,16 Louis M. Staudt, MD PhD,3
Wyndham H. Wilson, MD PhD32020
n/a
-
v
Binav Baral, MD,*,1 Prasanth Lingamaneni,*,2 Trilok Shrivastava, MD,*,3 Maryam Zia,4 Ishaan Vohra, MD,*,2
Krishna Rekha Moturi*,32020
903
n/a
-
v
Maxwell Green1, Scout Treadwell1, Geetha Gowda1, John Carlson, MD, PhD2
2023
610
n/a
-
v
Catherine Blackwood, PhD1 , Angela Lemons, MS2 , Rachael Rush3 , Walter McKinney2 , Dori Germolec4 , Donald Beezhold, PhD2 , Brett Green, PhD5 , Tara Croston, PhD6
2023
583
n/a
-
v
Catherine Blackwood, PhD1 , Angela Lemons, MS2 , Rachael Rush3 , Walter McKinney2 , Dori Germolec4 , Donald Beezhold, PhD2 , Brett Green, PhD5 , Tara Croston, PhD6
2023
583
n/a
-
v
Jennifer Roper, MD1, Sebastian Ochoa, MD2, Anahita
Agharahimi, MSN, CRNP2, Justina Pfister, RN2, Magdalena
Walkiewicz, PhD2, Amanda Urban, DNP, CRNP3, Rajarshi
Ghosh, PhD2, Michail Lionakis, MD, ScD2, Lisa Kohn, MD, PhD4, Kenneth Olivier, MD, MPH2, Alexandra Freeman, MD22023
516
n/a
-
v
Utkucan Acar, Gloria Sheng, Terrie Ahn, Lisa Kohn, Maria Garcia Lloret, Manish Butte
2022
82
n/a
